About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Clinicaltrials.gov identifier NCT03935282

Recruitment Status Enrolling by invitation

First Posted May 2, 2019

Last update posted March 5, 2021

Study Description

Brief summary:

The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in community oncology practices, using a group-randomized trial design (6 intervention practices and 6 usual care practices). Our central hypothesis is that the AH-HA tool will increase (1) cardiovascular health (CVH) discussions among survivors and oncology providers, (2) referrals and visits to primary care and cardiology (care coordination), and (3) cardiovascular (CV) risk reduction and health promotion activities compared to usual care.

  • Condition or Disease:Prostatic Neoplasm
    Colorectal Neoplasms
    Hodgkin Disease
    Non Hodgkin Lymphoma
    Endometrial Neoplasms
    Breast Neoplasm
  • Intervention/Treatment: Other: AH-HA Tool in the EPIC EHR
  • Phase: N/A
Detailed Description

In this hybrid effectiveness-implementation group-randomized clinical trial, 6 intervention practices will receive an EHR-based cardiovascular health assessment tool (Automated Heart Health Assessment for Survivors: AH-HA) and 6 practices will serve as usual care (control) practices without access to the AH-HA tool. AH-HA renders a visual, interactive display of CVH risk factors, automatically populated from the EHR. This tool was first implemented in primary care and now incorporates EHR data on receipt of cancer treatments with cardiotoxic potential. Providers at each intervention site will be trained to use the tool during routine follow-up care with survivors. Eligible survivors with breast, prostate, colorectal, endometrial, or Hodgkin and non-Hodgkin lymphoma cancer (n=600) will provide baseline data before and immediately after seeing their oncology provider and complete 6-month and 1-year study follow-up visits. The study team will compare changes in outcomes from baseline to 1-year in survivors at the intervention and usual care clinics using data from survivor self-reports and the EHR. The primary outcome is CVH discussions defined as the number of patient-reported discussions with their provider regarding up to seven non-ideal CVH conditions identified for that patient during oncology visits. Secondary outcomes include referrals to primary care and cardiology, provider efforts to manage CV risk, survivors' completed visits with primary care providers and cardiologists, and control of CVH factors and behaviors. Implementation metrics will be assessed using data from the EHR and semi-structured interviews with providers and administrators (n=24-30) at intervention clinics.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 640 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Supportive Care
  • Official Title: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (AH-HA)
  • Actual Study Start Date: October 2020
  • Estimated Primary Completion Date: May 2023
  • Estimated Study Completion Date: May 2023
Arms and interventions
Arm Intervention/treatment
Experimental: Intervention - AH-HA tool
With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
Other: AH-HA Tool in the EPIC EHR
The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
Outcome Measures
  • Primary Outcome Measures: 1. Proportion of patients reporting at least one non-ideal or missing CVH topic [ Time Frame: Baseline ]
    Discussion of non-ideal cardiovascular health (CVH) factors (yes or no). CVH discussions will be defined as patient-reported discussions with their provider for any of the seven non-ideal CVH conditions identified for that patient. Conditions include CVH factors (cholesterol, blood pressure, glucose/hemoglobin A1c) and CVH behaviors (body mass index, smoking, diet, and physical activity). Measured using survivor survey (discussions, diet, and primary care) and EHR for other CVH factors.
  • Secondary Outcome Measures: 1. Number of referrals to primary care and cardiology to manage CV risk [ Time Frame: 1 year ]
    Medical chart abstraction of referrals and communication with providers regarding CVH at each survivor visit.
  • 2. Number of CVH-relevant labs and treatments to manage CV risk [ Time Frame: 1 year ]
    Medical chart abstraction.
  • 3. Completed visits with primary care providers and cardiology [ Time Frame: 1 year ]
    Medical chart abstraction of referrals and communication with providers regarding CVH at each survivor visit.
  • 4. CVH behaviors recorded in the past year [ Time Frame: 1 year ]
    Medical chart abstraction; Patient survey as secondary, verification source. Measured using smoking status, BMI, physical activity, and healthy diet.
  • 5. CVH factors recorded in the past year [ Time Frame: 1 year ]
    Medical chart abstraction; Patient survey as secondary, verification source. Measured using total cholesterol, blood pressure, and fasting plasma glucose/Alc.
  • 6. Patient perception and knowledge of CV risks [ Time Frame: Baseline, 6 months, 1 year ]
    Measured using structured survivor survey. Health knowledge questions were adapted from a survey assessing the relative risk of cancer and cardiovascular disease in United States populations.Minimum score is 0, maximum score is 3 and answer is the total number of questions where a patient responded agree or strongly agree.
  • 7. Proportion of survivors for whom AH-HA is utilized [ Time Frame: 1 year ]
    We will capture the number of eligible patient visits during which the AH-HA tool was used in intervention clinics and the total number of eligible visits to calculate the proportion of patients where AH-HA was utilized.
  • 8. Measure of tool acceptability with Tool Assessment [ Time Frame: Baseline ]
    In the Baseline: Post-Visit Survey, survivors will complete a Tool Assessment questionnaire assessing whether or not they recall seeing or discussing the AH-HA tool with their provider and five questions assessing: how much they liked the tool, how helpful it was, how easy it was to understand, how much it improved their understanding, and if they would like to use this tool in the future. Patients will respond to 5 questions on a scale from strongly agree to strongly disagree.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- >= 6 months post-potentially curative cancer treatment for breast, prostate,
colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing
hormonal therapies such as tamoxifen, aromatase inhibitors, or androgen deprivation
are allowed.

- Scheduled for a routine cancer-related follow-up care visit within the next 30 days
with a provider who received training to use AH-HA.

- Able and willing to complete a follow-up assessment in one year.

- Survivors must have no evidence of disease at the time of last medical visit for all
cancers, except non-melanoma skin disease.

- Age >= 18 years.

- Able to understand and willing to provide verbal informed consent.

Exclusion Criteria:

- Survivors will be excluded if they have a history of cancer recurrence for any cancer
other than non-melanoma skin disease.

- Prostate patients on active surveillance will be excluded.

- Survivor does not speak English or Spanish.

- Survivors who are currently on another interventional protocol in which cardiovascular
risk factors (e.g., blood pressure, smoking, diet, physical activity) are being
addressed, as per patient self-report or research staff members' knowledge at the time
of consent.

Contacts and Locations
Contacts
Locations

United States, Iowa
Oncology Associates at Mercy Medical Center
Cedar Rapids

United States, Pennsylvania
Community Medical Center
Scranton

United States, Pennsylvania
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre

United States, Tennessee
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis

United States, Tennessee
Baptist Memorial Hospital for Women
Memphis

Sponsors and Collaborators

Wake Forest University Health Sciences

National Cancer Institute (NCI)

Washington University School of Medicine

University of Texas Southwestern Medical Center

Investigators

Principal Investigator: Kathryn Weaver, MD Wake Forest University Health Sciences

More Information